查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
癌症基因治療市場規模、份額和趨勢分析報告：按療法（溶瘤生物療法、基因引導免疫療法、基因轉移）、最終用途、地區、細分市場預測 2022-2030 年
市場調查報告書
商品編碼
1147481

癌症基因治療市場規模、份額和趨勢分析報告：按療法（溶瘤生物療法、基因引導免疫療法、基因轉移）、最終用途、地區、細分市場預測 2022-2030 年

Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer), By End-use, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

癌症基因治療市場的增長和趨勢

Grand View Research, Inc. 的一份新報告預測，到 2030 年，全球癌症基因治療市場將達到 87 億美元。由於全球對新療法的需求不斷增加以及全球癌症發病率不斷上升，該市場預計從 2022 年到 2030 年的複合年增長率為 19.99%。此外，這種療法為各種類型的遺傳性和誘發性癌症提供了明確的解決方案，使其成為更理想的癌症治療選擇。例如，Kite 的 Tecartus (brexucabtagene autoleucel) 已獲得 FDA 批准用於治療復發性或難治性前體 B 細胞急性淋巴細胞白血病。

預計全世界惡性腫瘤病例數量的增加將推動對有效治療和各種策略的需求，以對抗不斷增加的惡性腫瘤發病率。此外，市場上的技術進步有望為新療法提供新的機會。因此，產品批准的數量正在增加。例如，2022 年 3 月，歐洲醫學管理局建議有條件上市許可 Carvykti（ciltacabtagene autoleucel）用於治療復發難治性多發性骨髓瘤受試者。

這個市場受到世界各國政府和國家癌症協會的有利支持的積極推動。人們越來越關注增加癌症基因治療的研究經費。例如，2021 年 12 月，一個名為 DARE-NL 的荷蘭平台（荷蘭）從 KWF 荷蘭癌症協會獲得了 520 萬美元的贈款。這筆贈款將使 DARE-NL 能夠提升窮人可用的細胞和基因治療策略。

亞洲製造商專注於可大規模生產的低複雜性分子，因此對新技術和復雜技術的投資相對較低。因此，投資於高收益、低成本的技術是歐洲和北美等其他發達地區製造商規避競爭壓力的一種選擇。

在該市場運營的新興市場公司正專注於合作研究，以開發有效的癌症基因治療藥物。例如，2022 年 8 月，Gensaic 與 Ovid Therapeutics 簽訂合作研究協議，利用該公司專有的噬菌體衍生顆粒基因治療平台開發最多三種用於中樞神經系統適應症的基因治療藥物。

癌症基因治療市場報告亮點

由於對在基因水平上了解癌症狀況、基因引導免疫療法和個性化醫療的需求不斷增加，市場正面臨一個重大轉折點。

由於基因引導免疫治療研究的進展，基因引導免疫治療領域將在2021年佔據最大市場份額

由於對新型基因療法的需求不斷增加以及 FDA 批准癌症基因療法的數量不斷增加，生物製藥公司在 2021 年佔據了最大份額。由於該領域研發活動的增加，預計生物製藥公司在預測期內增長最快

由於主要參與者的存在以及政府和國家癌症研究所對推進該地區癌症研究的支持不斷增加，北美將在 2021 年主導該市場

目錄

1 癌症基因治療市場：研究方法和範圍

  • 市場細分
    • 段範圍
    • 區域範圍
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • GVR內部數據庫
    • 次要信息
    • 初步調查
    • 第一次調查的內容
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 型號詳情
    • 商品流向分析
      • 方法一：商品流動方法
      • 方法 2：使用自下而上的方法按國家/地區進行市場預測
      • 方法 2：使用自上而下的方法逐個國家/地區進行市場估算
  • 全球市場：複合年增長率計算
  • 區域市場：CAGR 計算
  • 二級信息列表
  • 目的
  • 縮略語表

2 癌症基因治療市場：執行摘要

  • 癌症基因治療市場：市場前景
    • 市場概況

3 癌症基因治療市場：行業展望

  • 市場系列展望
    • 父市場血統展望
    • 相關/子公司市場展望
  • 繪製滲透率和增長前景
  • 市場動態
    • 市場驅動力
      • 醫藥行業高增長
      • 研發投入增加，抗癌新藥需求增加
      • 癌症發病率增加
      • 技術進步
    • 市場約束因素分析
      • 產品價格高
      • 不道德地使用基因療法
  • SWOT 分析，按因素（政治和法律、經濟和技術）
  • 行業分析 - 搬運工
  • 贖回和監管場景
  • 重大交易和戰略聯盟
    • 新產品發布
    • 獲得
    • 擴張
    • 合夥
    • 營銷和推廣

第四章癌症基因治療市場：競爭格局

  • 主要市場進入者的最新發展和影響分析
    • Ansoff Matrix
  • 公司分類
    • 創新者
      • 市場差異化因素
  • 供應商情況
    • 主要經銷商及渠道合作夥伴名單
    • 主要客戶
    • 2021 年主要參與者的市場份額分析
  • 上市公司
    • 競爭儀錶盤分析
  • 民營企業
    • 主要初創企業名單
  • Regional Network Map

5 癌症基因治療市場：治療分析

  • 癌症基因治療市場：治療波動分析
  • 溶瘤病毒療法
  • 基因引導的免疫療法
  • 基因轉移

6 癌症基因治療市場：最終用途分析

  • 癌症基因治療市場：最終用途變異分析
  • 調查
  • 生物製藥公司
  • 診斷中心
  • 其他最終用途

第 7 章癌症基因治療市場：區域業務分析

  • 2021 年和 2030 年按國家/地區劃分的市場份額分析
    • 北美
      • 美國
      • 加拿大
    • 歐洲
      • 英國
      • 德國
      • 法國
      • 意大利
      • 西班牙
    • 亞太地區
      • 日本
      • 中國
      • 印度
      • 韓國
      • 澳大利亞
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
    • 中東和非洲
      • 南非
      • 沙特阿拉伯
      • 阿拉伯聯合酋長國

8 癌症基因治療市場：公司概況

  • 公司簡介
    • Abeona Therapeutics Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Asklepios BioPharmaceutical Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Celgene（Bristol-Myers Squibb Company）
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Elevate Bio
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • GlaxoSmithKline Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Bluebird bio Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Genelux Corporation
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • OncoGenex Pharmaceuticals Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Introgen Therapeutics Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Altor Bioscience Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Merck &Co., Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • GenVec
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • BioCancell Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
  • 其他主要參與者名單
Product Code: GVR-4-68039-984-2

Cancer Gene Therapy Market Growth & Trends:

The global cancer gene therapy market size is expected to reach USD 8.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 19.99% from 2022 to 2030 owing to the increasing demand for novel therapeutics globally and rising incidence of cancer cases globally. Moreover, this therapy offers an absolute solution to different kinds of inherited and induced cancer conditions, which makes it a more desired option for cancer therapeutics. For instance, Kite's Tecartus (brexucabtagene autoleucel) is approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

There is an increasing prevalence of malignant tumor cases across the globe, which is expected to propel the need for various strategies for effective treatment and to combat the increasing incidence of malignant tumors. Moreover, technological advancements in the market are expected to provide new opportunities for novel therapeutics. As a result, there is an increasing number of product approvals. For instance, in March 2022, European Medicine Agency recommended conditional marketing authorization for Carvykti (ciltacabtagene autoleucel) to be used for the treatment of subjects with relapsed and refractory multiple myeloma.

The market is positively driven by the lucrative support from the government and national cancer societies across the globe. There has been an increasing focus on increasing funds for research on cancer gene therapy. For instance, in December 2021, The Dutch platform called DARE-NL (in the Netherlands) has been awarded a USD 5.2 million grant from the KWF Dutch cancer society. The grant allows the DARE-NL to level up the availability of cell and gene therapy strategies accessible to the needy population.

The investment in new and complex technologies is relatively low for Asian manufacturers as they are more focused on less complex molecules that can be produced in bulk. Thus, the investment in high-yielding, low-cost technologies is an alternative for manufacturers in other developed regions such as Europe and North America to avoid competitive pressure.

Key players operating in the market are focusing on collaborations for the development of potent cancer gene therapy drugs. For instance, in August 2022, Gensaic signed a collaboration with Ovid Therapeutics for the development of up to three genetic medicines for central nervous system indications using its proprietary phage-derived particle gene therapy platform.

Cancer Gene Therapy Market Report Highlights:

  • The market is witnessing a key shift with the rise in gene level understanding of a cancer condition and rising need for gene induced immunotherapy and personalized medicine
  • The gene induced immunotherapy segment held the largest share in 2021 due to increase in the advancement in gene induced immunotherapy research
  • Biopharmaceutical companies held the largest market share in 2021 owing to rising demand for novel gene therapy and increasing number of FDA approvals for cancer gene therapy. Biopharmaceutical companies are anticipated to witness the fastest growth in the forecast period due to increasing research and development activities in the field
  • North America dominated the market in 2021 due to the presence of key players and rising support from the government and National Cancer Institute to advance the research on oncology in the region

Table of Contents

Chapter 1 Cancer Gene Therapy Market: Methodology And Scope

  • 1.1 Market Segmentation
    • 1.1.1 Segment Scope
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
      • 1.6.1.3 Approach 2: Country Wise Market Estimation Using Top Down Approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Regional Market: CAGR Calculation
  • 1.9 List of Secondary Sources
  • 1.10 Objectives
    • 1.10.1 Objective 1:
    • 1.10.2 Objective 2:
  • 1.11 List of Abbreviations

Chapter 2 Cancer Gene Therapy Market: Executive Summary

  • 2.1 Cancer Gene Therapy Market: Market Outlook
    • 2.1.1 Market Summary

Chapter 3 Cancer Gene Therapy Market: Industry Outlook

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Lineage Outlook
    • 3.1.2 Related/Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Market Dynamics
    • 3.3.1 Market Drivers
      • 3.3.1.1 High growth of the pharmaceutical industry
      • 3.3.1.2 Rising R&D investements and demand for novel cancer therapeutics
      • 3.3.1.3 Increased incidence of cancers
      • 3.3.1.4 Technological advancements
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 High product prices
      • 3.3.2.2 Unethical use of gene therapy
  • 3.4 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • 3.5 Industry Analysis - Porter's
  • 3.6 Reimbursement & Regulatory Scenario
  • 3.7 Major Deals & Strategic Alliances
    • 3.7.1 New Product Launch
    • 3.7.2 Acquisition
    • 3.7.3 Expansion
    • 3.7.4 Partnerships
    • 3.7.5 Marketing & Promotions

Chapter 4 Cancer Gene Therapy Market: Competitive Landscape

  • 4.1 Recent Developments & Impact Analysis, By Key Market Participants
    • 4.1.1 Ansoff Matrix
  • 4.2 Company Categorization
    • 4.2.1 Innovators
      • 4.2.1.1 Market Differentiators
  • 4.3 Vendor Landscape
    • 4.3.1 List Of Key Distributors And Channel Partners
    • 4.3.2 Key Customers
    • 4.3.3 Key Company Market Share Analysis, 2021
  • 4.4 Public Companies
    • 4.4.1 Competitive Dashboard Analysis
  • 4.5 Private Companies
    • 4.5.1 List Of Key Emerging Companies
  • 4.6 Regional Network Map

Chapter 5 Cancer Gene Therapy Market: Therapy Analysis

  • 5.1 Cancer Gene Therapy Market: Therapy Movement Analysis
  • 5.2 Oncolytic Virotherapy
    • 5.2.1 Oncolytic virotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3 Gene Induced Immunotherapy
    • 5.3.1 Gene induced immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4 Gene Transfer
    • 5.3.1 Gene transfer market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 Cancer Gene Therapy Market: End-Use Analysis

  • 6.1 Cancer Gene Therapy Market: End-Use Movement Analysis
  • 6.2 Research Institutes
    • 6.2.1 Research institutes based cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3 Biopharmaceutical Companies
    • 6.3.1 Biopharmaceutical companies based cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4 Diagnostic Centres
    • 6.4.1 Diagnostic centres based cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5 Other End-use
    • 6.5.1 Other end-use based cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 Cancer Gene Therapy Market: Regional Business Analysis

  • 7.1 Market Share Analysis by Country, 2021 & 2030
    • 7.1.1 North America
      • 7.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.1.2 U.S.
      • 7.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.1.3 Canada
      • 7.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.2 Europe
      • 7.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.2 U.K.
      • 7.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.3 Germany
      • 7.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.4 France
      • 7.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.5 Italy
      • 7.1.2.5.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.6 Spain
      • 7.1.2.6.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.3 Asia Pacific
      • 7.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.2 Japan
      • 7.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.3 China
      • 7.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.4 India
      • 7.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.5 South Korea
      • 7.1.3.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.6 Australia
      • 7.1.3.6.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.4 Latin America
      • 7.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.4.2 Brazil
      • 7.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.4.3 Mexico
      • 7.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.4.4 Argentina
      • 7.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.5 Middle East And Africa
      • 7.1.5.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.5.2 South Africa
      • 7.1.5.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.5.3 Saudi Arabia
      • 7.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.5.4 UAE
      • 7.1.5.4.1 UAE market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Cancer Gene Therapy Market: Company Profiling

  • 8.1 Company Profiles
    • 8.1.1 Abeona Therapeutics Inc.
      • 8.1.1.1 Company overview
      • 8.1.1.2 Financial performance
      • 8.1.1.3 Product benchmarking
      • 8.1.1.4 Strategic initiatives
    • 8.1.2 Asklepios BioPharmaceutical Inc.
      • 8.1.2.1 Company overview
      • 8.1.2.2 Financial performance
      • 8.1.2.3 Product benchmarking
      • 8.1.2.4 Strategic initiatives
    • 8.1.3 Celgene(Bristol-Myers Squibb Company)
      • 8.1.3.1 Company overview
      • 8.1.3.2 Financial performance
      • 8.1.3.3 Product benchmarking
      • 8.1.3.4 Strategic initiatives
    • 8.1.4 Elevate Bio
      • 8.1.4.1 Company overview
      • 8.1.4.2 Financial performance
      • 8.1.4.3 Product benchmarking
      • 8.1.4.4 Strategic initiatives
    • 8.1.5 GlaxoSmithKline Inc.
      • 8.1.5.1 Company overview
      • 8.1.5.2 Financial performance
      • 8.1.5.3 Product benchmarking
      • 8.1.5.4 Strategic initiatives
    • 8.1.6 Bluebird bio Inc.
      • 8.1.6.1 Company overview
      • 8.1.6.2 Financial performance
      • 8.1.6.3 Product benchmarking
      • 8.1.6.4 Strategic initiatives
    • 8.1.7 Genelux Corporation
      • 8.1.7.1 Company overview
      • 8.1.7.2 Financial performance
      • 8.1.7.3 Product benchmarking
      • 8.1.7.4 Strategic initiatives
    • 8.1.8 OncoGenex Pharmaceuticals Inc.
      • 8.1.8.1 Company overview
      • 8.1.8.2 Financial performance
      • 8.1.8.3 Product benchmarking
      • 8.1.8.4 Strategic initiatives
    • 8.1.9 Introgen Therapeutics Inc.
      • 8.1.9.1 Company overview
      • 8.1.9.2 Financial performance
      • 8.1.9.3 Product benchmarking
      • 8.1.9.4 Strategic initiatives
    • 8.1.10 Altor Bioscience Inc.
      • 8.1.10.1 Company overview
      • 8.1.10.2 Financial performance
      • 8.1.10.3 Product benchmarking
      • 8.1.10.4 Strategic initiatives
    • 8.1.11 Merck & Co., Inc.
      • 8.1.11.1 Company overview
      • 8.1.11.2 Financial performance
      • 8.1.11.3 Product benchmarking
      • 8.1.11.4 Strategic initiatives
    • 8.1.12 GenVec
      • 8.1.12.1 Company overview
      • 8.1.12.2 Financial performance
      • 8.1.12.3 Product benchmarking
      • 8.1.12.4 Strategic initiatives
    • 8.1.13 BioCancell Inc.
      • 8.1.13.1 Company overview
      • 8.1.13.2 Financial performance
      • 8.1.13.3 Product benchmarking
      • 8.1.13.4 Strategic initiatives
  • 8.2 List of Other Key Players

List of Tables

  • TABLE 1 List of Secondary Sources
  • TABLE 2 List of Abbreviations
  • TABLE 3 Incidence of Diseases
  • TABLE 4 Global Cancer Gene Therapy Market, By Region, 2018 - 2030 (USD Million)
  • TABLE 5 Global Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 6 Global Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 7 North America Cancer Gene Therapy Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 8 North America Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 9 North America Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 10 U.S. Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 11 U.S. Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 12 Canada Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 13 Canada Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 14 Europe Cancer Gene Therapy Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 15 Europe Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 16 Europe Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 17 Germany Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 18 Germany Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 19 U.K. Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 20 U.K. Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 21 France Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 22 France Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 23 Italy Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 24 Italy Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 25 Spain Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 26 Spain Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 27 Asia Pacific Cancer Gene Therapy Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 28 Asia Pacific Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 29 Asia pacific Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 30 Japan Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 31 Japan Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 32 China Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 33 China Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 34 India Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 35 India Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 36 South Korea Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 37 South Korea Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 38 Australia Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 39 Australia Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 40 Latin America Cancer Gene Therapy Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 41 Latin America Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 42 Latin America Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 43 Brazil Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 44 Brazil Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 45 Mexico Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 46 Mexico Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 47 Argentina Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 48 Argentina Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 49 Middle East & Africa Cancer Gene Therapy Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 50 Middle East & Africa Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 51 Middle East & Africa Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 52 Saudi Arabia Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 53 Saudi Arabia Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 54 South Africa Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 55 South Africa Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 56 UAE Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 57 UAE Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 Information Procurement
  • FIG. 2 Primary Research Pattern
  • FIG. 3 Market Research Approaches
  • FIG. 4 Value Chain-Based Sizing & Forecasting
  • FIG. 5 Market Formulation & Validation
  • FIG. 6 Cancer Gene Therapy, Market Segmentation
  • FIG. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • FIG. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • FIG. 9 Market Challenge Relevance Analysis (Current & Future Impact)
  • FIG. 10 Penetration & Growth Prospect Mapping
  • FIG. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • FIG. 12 Porter's Five Forces Analysis
  • FIG. 13 Market Penetration Vs Growth Prospect Mapping, 2021
  • FIG. 14 Regional Marketplace: Key Takeaways
  • FIG. 15 Global Cancer Gene Therapy Market, for Therapy, 2018 - 2030 (USD Million)
  • FIG. 16 Global Cancer Gene Therapy Market, for Oncolytic Virotherapy, 2018 - 2030 (USD Million)
  • FIG. 17 Global Cancer Gene Therapy Market, for Gene Induced Immunotherapy, 2018 - 2030 (USD Million)
  • FIG. 18 Global Cancer Gene Therapy Market, for Gene Transfer, 2018 - 2030 (USD Million)
  • FIG. 19 Global Cancer Gene Therapy Market, for End-Use, 2018 - 2030 (USD Million)
  • FIG. 20 Global Cancer Gene Therapy Market, for Research Institutes, 2018 - 2030 (USD Million)
  • FIG. 21 Global Cancer Gene Therapy Market, for BiopharmaceuticalCompanies, 2018 - 2030 (USD Million)
  • FIG. 22 Global Cancer Gene Therapy Market, for Diagnostic Centers, 2018 - 2030 (USD Million)
  • FIG. 23 Regional Outlook, 2021 & 2030
  • FIG. 24 North America Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 25 U.S. Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 26 Canada Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 27 Europe Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 28 Germany Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 29 U.K. Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 30 France Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 31 Italy Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 32 Spain Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 33 Asia Pacific Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 34 Japan Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 35 China Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 36 India Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 37 Australia Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 38 South Korea Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 39 Latin America Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 40 Brazil Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 41 Mexico Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 42 Argentina Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 43 Middle East and Africa Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 44 South Africa Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 45 Saudi Arabia Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 46 UAE Cancer Gene Therapy Market, 2018 - 2030 (USD Million)